Compound · clinical trials

Limertinib clinical trials

Also listed in trial records as ASK120067

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 7 trials in our China register that name Limertinib as an intervention. Synced 9 Nov 2026

7Current trials

2Recruiting now

5Lead sponsors

1Country register

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Limertinib is named as an intervention in 7 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Jiangsu Aosaikang Pharmaceutical Co., Ltd (3). The most-studied condition is EGFR Activating Mutation.

Patient leaflets for Limertinib

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting229%
Not yet open571%

Trials by phase

Phase 2343%
Phase 3229%
Phase 1114%
Phase 1/2114%

Clinical trials of Limertinib

7 trials

Study	Phase	Status	Lead sponsor	Registers
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy NCT07109531 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic NSCLC	Phase 3	Recruiting	Jiangsu Aosaikang Pharmaceutical Co., Ltd	China
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067 NCT05306132 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	Jiangsu Aosaikang Pharmaceutical Co., Ltd	China
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC NCT07897188 · ClinicalTrials.gov ↗ · EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive	Phase 3	Not yet open	Jiangsu Aosaikang Pharmaceutical Co., Ltd	China
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression NCT07001995 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC	Phase 2	Not yet open	Hunan Province Tumor Hospital	China
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC NCT07038460 · ClinicalTrials.gov ↗ · Resectable Non-small Cell Lung Cancer	Phase 2	Not yet open	Wen-zhao ZHONG	China
Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases NCT07413952 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Not yet open	The First Affiliated Hospital of Guangzhou Medical University	China
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors NCT07612137 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Not yet open	Innovent Biologics (Suzhou) Co. Ltd	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Limertinib

11 conditions

EGFR Activating Mutation1Non-Squamous Non-Small Cell Lung Cancer (NSCLC)1MET Positive1Locally Advanced or Metastatic NSCLC1Resectable Non-small Cell Lung Cancer1Small Cell Lung Cancer1 Non Small Cell Lung Cancer1 Non Small Cell Lung Cancer NSCLC1 Advanced Solid Tumor1 Solid Tumor1 NSCLC1

By country register

Register	Trials	Recruiting
Clinical trials in China	7	2

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Limertinib trials

How many clinical trials are testing Limertinib?

7 current trials in our China register name Limertinib (also registered as ASK120067) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Limertinib trials recruiting patients?

Yes. 2 of the 7 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Limertinib clinical trials?

Jiangsu Aosaikang Pharmaceutical Co., Ltd (3), Wen-zhao ZHONG (1), Hunan Province Tumor Hospital (1) and Innovent Biologics (Suzhou) Co. Ltd (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Limertinib works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Limertinib works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Limertinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.